US Stocks

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that specializes in the development and commercialization of therapeutic treatments for metabolic, liver, and cardiovascular diseases. The company's leading product candidate, resmetirom, is currently in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. Madrigal Pharmaceuticals has a research, development, and commercialization agreement with Hoffmann-La Roche and is based in West Conshohocken, Pennsylvania.